Population PK/PD modelling of the anti-IL-33 antibody tozorakimab to predict pulmonary target engagement in patients with COPD

M. Sadiq (Gothenburg, Sweden), H. Yu (Gaithersburg, United States), M. Astrand (Gothenburg, Sweden), I. Scott (Cambridge, United Kingdom), A. Williams (Cambridge, United Kingdom), L. Hewitt (Gaithersburg, United States), N. White (Cambridge, United Kingdom), H. Killick (Cambridge, United Kingdom), M. Gavala (Gaithersburg, United States), F. Reid (Cambridge, United Kingdom), C. Kell (Cambridge, United Kingdom), H. Pandya (Cambridge, United Kingdom), E. Jimenez (Barcelona, Spain)

Source: International Congress 2022 – Update on clinical trials in allergy, asthma and COPD

Session: Update on clinical trials in allergy, asthma and COPD
Session type: Thematic Poster
Number: 3201

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Sadiq (Gothenburg, Sweden), H. Yu (Gaithersburg, United States), M. Astrand (Gothenburg, Sweden), I. Scott (Cambridge, United Kingdom), A. Williams (Cambridge, United Kingdom), L. Hewitt (Gaithersburg, United States), N. White (Cambridge, United Kingdom), H. Killick (Cambridge, United Kingdom), M. Gavala (Gaithersburg, United States), F. Reid (Cambridge, United Kingdom), C. Kell (Cambridge, United Kingdom), H. Pandya (Cambridge, United Kingdom), E. Jimenez (Barcelona, Spain). Population PK/PD modelling of the anti-IL-33 antibody tozorakimab to predict pulmonary target engagement in patients with COPD. 3201

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.